Skip to main content
Top
Published in: Thrombosis Journal 1/2021

Open Access 01-12-2021 | Computed Tomography | Research

Malignant tumor is the greatest risk factor for pulmonary embolism in hospitalized patients: a single-center study

Authors: Kaoru Fujieda, Akiko Nozue, Akie Watanabe, Keiko Shi, Hiroya Itagaki, Yoshihiko Hosokawa, Keiko Nishida, Nobutaka Tasaka, Toyomi Satoh, Ken Nishide

Published in: Thrombosis Journal | Issue 1/2021

Login to get access

Abstract

Background

This study aimed to investigate the background of patients who presented with pulmonary embolism (PE) on contrast-enhanced chest computed tomography (CT) and to explore the risk factors for PE.

Methods

This study included a review of the medical records of all 50,621 patients who were admitted to one community hospital between January 1, 2013 and December 31, 2017. Data on sex, age, risk factors related to blood flow stagnation (obesity, long-term bed rest, cardiopulmonary disease, cast fixation, long-term sitting), risk factors related to vascular endothelial disorder (surgery, trauma/fracture, central venous catheterization, catheter tests/treatments, vasculitis, antiphospholipid antibody syndrome, history of venous thromboembolism (VTE)), and risk factors related to hypercoagulability (malignant tumor, use of oral contraceptives/low-dose estrogen progestin/steroids, infection, inflammatory enteric disease, polycythemia, protein C or protein S deficiency, dehydration) were evaluated.

Results

Of all inpatients, 179(0.35%) out of 50,621 were diagnosed with PE after contrast-enhanced chest CT examination, in which 74 patients were symptomatic and 105 patients had no symptom. Among asymptomatic 105 patients, 71 patients got CT scans for other reasons including cancer screening and searching infection focus, and 34 patients got CT scans for searching PE due to either apparent or suspicious DVT. The rate of discovering PE was significantly greater in women (0.46%, 90/19,409) than men (0.29%, 89/31,212) (P = 0.008). Of the 179 patients with PE, 164 (92%) had some type of risk factor. For both men and women, the most frequent risk factor was a malignant tumor, followed by obesity, long-term bed rest and infection for men and long-term bed rest, obesity and infection for women. The most common malignant tumor was lung cancer. Although taking antipsychotic agent is not advocated as a risk factor, there is a possibility of involvement.

Conclusions

The risk factors for PE were identified in this single-center, retrospective study.
Literature
6.
go back to reference Virchow R. Gesammalte Abhandlungen Zur Wissenschaftlichen Medizin. Frankfurt: Medinger Sohn & CO; 1856. p. 219–732. Virchow R. Gesammalte Abhandlungen Zur Wissenschaftlichen Medizin. Frankfurt: Medinger Sohn & CO; 1856. p. 219–732.
7.
go back to reference Maisso M, Renato P, Brouno F, Carlo M, Giorgio DR, Lucia T, et al. Accuracy of clinical assessment in the diagnosis of pulmonary embolism. Am J Respir Crit Care Med. 1999;159(3):864–71.CrossRef Maisso M, Renato P, Brouno F, Carlo M, Giorgio DR, Lucia T, et al. Accuracy of clinical assessment in the diagnosis of pulmonary embolism. Am J Respir Crit Care Med. 1999;159(3):864–71.CrossRef
24.
go back to reference Chanakira A, Westmark PR, Ong IM, Sheehan JP. Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer. Gynecol Oncol. 2007;145(1):167–75.CrossRef Chanakira A, Westmark PR, Ong IM, Sheehan JP. Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer. Gynecol Oncol. 2007;145(1):167–75.CrossRef
Metadata
Title
Malignant tumor is the greatest risk factor for pulmonary embolism in hospitalized patients: a single-center study
Authors
Kaoru Fujieda
Akiko Nozue
Akie Watanabe
Keiko Shi
Hiroya Itagaki
Yoshihiko Hosokawa
Keiko Nishida
Nobutaka Tasaka
Toyomi Satoh
Ken Nishide
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2021
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-021-00334-2

Other articles of this Issue 1/2021

Thrombosis Journal 1/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.